Stokes Peebles Archives

Study finds RSV may evade vaccines via rapid mutation

Mar. 9, 2023—A Vanderbilt study concluded that RSV’s ability to mutate rapidly to escape detection by the body’s immune system makes it more challenging to design and develop vaccines that can stop it from spreading.

The clinical trial group includes, from left, Gordon Bernard, MD, Katherine Cahill, MD, Kevin Niswender, MD, PhD, Pingsheng Wu, PhD, and R. Stokes Peebles, MD.

Clinical trial at VUMC tests novel treatment for asthma

Nov. 10, 2022—VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.

A clinical trial supports approval of a new medication to treat moderate-to-severe asthma in children.

Study explores role RSV plays in later asthma development

Jul. 21, 2022—A Vanderbilt clinical project will follow 1,950 Middle Tennessee children to determine how genes and the environment interact with RSV infection during the first year of life and contribute to asthma development

Drake, Freedman, Peebles elected AAP members

Apr. 21, 2022—Vanderbilt's Wonder Drake, MD, Jane Freedman, MD, and Stokes Peebles, MD, have been elected to membership in the Association of American Physicians (AAP), one of the nation’s most respected medical honor societies.

Allison Norlander, PhD, R. Stokes Peebles, MD, and colleagues are studying an approved drug that enhances immune cells and might be useful for treating inflammatory and autoimmune diseases.

Team studies new use for pulmonary hypertension drug

Mar. 25, 2021—An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.

3d rendering white blood cells with red blood cells

A new regulator of B cell development

Oct. 8, 2019—New findings establish a role for the pro-inflammatory molecule IL-33 in the early development of antibody-producing B cells.

Connecting an asthma gene to leukemia

Aug. 2, 2018—A receptor previously implicated in asthma may also play roles in other allergic diseases and in leukemia, Vanderbilt researchers have discovered.

Team explores diabetes drug’s ability to treat RSV infection

Jul. 12, 2018—A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

Asthma study may point to potential new therapeutic approach

Jan. 4, 2018—New findings from Vanderbilt suggest that blocking the migration of cells involved in asthma may represent a new approach for treating the respiratory condition.

Study to track diabetes drug’s ability to also treat asthma

Jan. 19, 2017—Investigators in the Division of Allergy, Pulmonary, and Critical Care Medicine and the Division of Diabetes, Endocrinology, and Metabolism recently received a $1.25 million grant from the National Institute of Allergy and Infectious Diseases.

Team to study RSV’s role in asthma formation

Jul. 21, 2016—Investigators in the Division of Allergy, Pulmonary and Critical Care Medicine recently received a $4.5 million Asthma and Allergic Diseases Cooperative Research Center (AADCRC) grant from the National Institutes of Allergy and Infectious Diseases (NIAID).

Immune defenses in asthma

Apr. 5, 2016—Vanderbilt researchers show that a certain factor negatively impacts the first-line responder cells in the lungs, providing one explanation for why patients with asthma are at greater risk for invasive bacterial disease.